Clinical stage company developing the next-gen Photodynamic Therapy (PDT), called Photosoft, for the treatment of a range of cancers & infectious diseases
Results from Ph 2 prostate cancer trial using INV043 showed it to be safe & well tolerated by patients, 40% showed a positive response using RECIST 1.1 (10% complete regression) & 44% negative on PSMA-PET. investors.inviongroup.com/an…#asx#smallcaps#CancerResearch#investing
.@InvionLimited & the Hudson Institute, have announced significant in vitro data for the new IVXP02 PhotosoftTM formulation, including a validated at 15x potency compared to other PDT treatments for ovarian cancer cells. See more here - youtu.be/dbvDMAr4DXQ#IVX#ASX#ausbio